SEC Form	4
----------	---

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			of Section 50(n) of the investment company Act of 1940						
1. Name and Address of Reporting Person* <u>Weber Darin J.</u> (Last) (First) (Middle) C/O PROKIDNEY CORP 2000 FRONTIS PLAZA BLVD, SUITE 250 (Street)		Person*	2. Issuer Name and Ticker or Trading Symbol <u>PROKIDNEY CORP.</u> [PROK]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/01/2024	X Officer (give title Other (specify below) below) SVP of Regulatory Development					
		D, SUITE 250	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
WINSTON- SALEM	NC	27103		Form filed by More than One Reporting Person					
SALEM			Rule 10b5-1(c) Transaction Indication	idication					
(City)	(State)	(Zip)	X Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See	t to a contract, instruction or written plan that is intended to Instruction 10.					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Dat if any (Month/Day/Year)		n Date, Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(1150. 4)	
Class A Ordinary Shares	04/01/2024		S		300	D	\$1.69	273,773	D ⁽¹⁾		
Class A Ordinary Shares	04/12/2024		S		84,103	D	\$1.73 ⁽²⁾	189,670	D ⁽¹⁾		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		Transaction Code (Instr.		Date, Transactio Code (Inst		of Deriv Secu Acqu (A) o Dispe	Derivative (Month/Day/Year) Securities Cupuired A) or Disposed of (D) Instr. 3, 4		Expiration Date Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares								

Explanation of Responses:

1. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.69 to \$1.77, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.



04/16/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.